Castle Biosciences
CSTL· Services· Fiscal year ends in December
Derek J. Maetzold is the CEO of Castle Biosciences and was paid $6.8M in FY2025 (Dec), down 2%.
Executives4
See all- 1Derek J. MaetzoldPresident and CEOFY2025
- 2Frank StokesChief Financial OfficerFY2025
- 3Kristen M. OelschlagerChief Operating OfficerFY2025
- 4Tobin W. JuvenalChief Commercial OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allCastle Biosciences paid its 4 named executives $13.9M in total in FY2025 (Dec). CEO Derek J. Maetzold was paid $6.8M of that.
| Name | |||
|---|---|---|---|
| Derek J. MaetzoldPresident and CEO | |||
| Frank StokesChief Financial Officer | |||
| Kristen M. OelschlagerChief Operating Officer | |||
| Tobin W. JuvenalChief Commercial Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers17
See allThe FY2024 (Dec) proxy of Castle Biosciences names 17 peer companies for pay. Among Castle Biosciences and these peers, CEO pay was 7th highest of 9 and total shareholder return was 5th highest of 9.
7th highest of 9in Castle Biosciences and its pay peers, FY2024 (Dec) by CEO pay:
5th highest of 9in Castle Biosciences and its pay peers, FY2024 (Dec) by total shareholder return:
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board1
See all- Ellen GoldbergDirector · 4 yr on the boardIndependentCompensation (Chair), Nominating and Corporate Governance—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 8, 2026 | FY2025 |
| Annual report | 10-K | Feb 26, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 9, 2025 | FY2024 |
| Annual report | 10-K | Feb 27, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 10, 2024 | FY2023 |
| Annual report | 10-K | Feb 28, 2024 | FY2023 |